PROJECT NARRATIVE Ovarian cancer is the most lethal gynecologic malignancy, with few known modifiable risk factors, and no effective screening methods or unique symptoms for detection in early stages. Better therapeutic options are needed for the less studied histological types of ovarian cancer that show variable or poor response to platinum-taxane based therapy. Our approach uses integrated analysis of multiple layers of information, including relationships between risk factors and genomic and prognostic associations, to provide powerful biological and mechanistic insight into ovarian cancer biology with potential to point to novel targeted therapeutic options.
|Effective start/end date||1/13/21 → 12/31/22|
- National Cancer Institute: $916,810.00
- National Cancer Institute: $1,070,801.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.